This inventor holds 1 USPTO granted patent. Top assignee: Genzyme Corporation. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Nigel Patrick Somerville Crawford: Patent Activity in Lysosomal Storage Disease Treatment
Introduction
Nigel Patrick Somerville Crawford is an inventor associated with Califon, New Jersey, and Genzyme Corporation. His patent work concerns methods for treating symptoms and disorders associated with lysosomal storage diseases.
Latest Patents
Crawford is named on one patent: “Methods for Treating Symptoms and Disorders Associated with Lysosomal Storage Diseases.” The disclosure describes using quinuclidine compounds, optionally alongside enzyme replacement therapy, to treat or prevent certain symptoms and disorders in patients with lysosomal storage diseases. Examples include abdominal pain and dermatological conditions such as angiokeratoma in patients with Fabry disease. The patent also describes pharmaceutical compositions containing a quinuclidine compound for these uses. Crawford’s listed patent portfolio comprises 1 patent.
Career Highlights
Crawford’s documented patent activity is connected with Genzyme Corporation and focuses on potential therapeutic approaches for symptoms associated with lysosomal storage diseases.
Collaborations
Tanya Zaremba Fischer is identified as Crawford’s coworker. The patent disclosure reflects work in a therapeutic area that may involve collaboration among researchers and pharmaceutical professionals.
Conclusion
Nigel Patrick Somerville Crawford’s patent record highlights an invention directed toward treating symptoms associated with lysosomal storage diseases, including Fabry disease.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile